{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:04:11Z","timestamp":1778691851154,"version":"3.51.4"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ucl.2017.07.003","type":"journal-article","created":{"date-parts":[[2017,10,26]],"date-time":"2017-10-26T23:32:06Z","timestamp":1509060726000},"page":"547-555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Whom to Treat"],"prefix":"10.1016","volume":"44","author":[{"given":"Annika","family":"Herlemann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Samuel L.","family":"Washington","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renu S.","family":"Eapen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Cooperberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ucl.2017.07.003_bib1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1001\/jama.1995.03520310046028","article-title":"The role of increasing detection in the rising incidence of prostate cancer","volume":"273","author":"Potosky","year":"1995","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ucl.2017.07.003_bib2","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.ucl.2017.07.003_bib3","first-page":"433","article-title":"An update of the Gleason grading system","volume":"183","author":"Epstein","year":"2010","journal-title":"J\u00a0Urol"},{"issue":"2 Suppl","key":"10.1016\/j.ucl.2017.07.003_bib4","first-page":"18","article-title":"Novel concepts for risk stratification in prostate cancer","volume":"9","author":"Patel","year":"2016","journal-title":"J\u00a0Clin Urol"},{"issue":"4","key":"10.1016\/j.ucl.2017.07.003_bib5","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ucl.2017.07.003_bib6","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/01.pas.0000173646.99337.b1","article-title":"The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma","volume":"29","author":"Epstein","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ucl.2017.07.003_bib7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/MOU.0000000000000388","article-title":"Improving the evaluation and diagnosis of clinically significant prostate cancer","volume":"27","author":"Kryvenko","year":"2017","journal-title":"Curr Opin Urol"},{"issue":"2","key":"10.1016\/j.ucl.2017.07.003_bib8","first-page":"548","article-title":"The impact of the 2005 International Society of Urological Pathology consensus conference on standard Gleason grading of prostatic carcinoma in needle biopsies","volume":"180","author":"Billis","year":"2008","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2017.07.003_bib9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00428-015-1809-5","article-title":"Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3\u00a0+ 4\u00a0= 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy","volume":"467","author":"Keefe","year":"2015","journal-title":"Virchows Arch"},{"issue":"6","key":"10.1016\/j.ucl.2017.07.003_bib10","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/modpathol.2016.49","article-title":"Disease-specific survival of patients with invasive cribriform and intraductal prostate cancer at diagnostic biopsy","volume":"29","author":"Kweldam","year":"2016","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1016\/j.ucl.2017.07.003_bib11","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.prp.2014.06.002","article-title":"The association of the cribriform pattern with outcome for prostatic adenocarcinomas","volume":"210","author":"Kir","year":"2014","journal-title":"Pathol Res Pract"},{"issue":"10","key":"10.1016\/j.ucl.2017.07.003_bib12","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/PAS.0000000000000691","article-title":"Prognostic significance of percentage and architectural types of contemporary Gleason pattern 4 prostate cancer in radical prostatectomy","volume":"40","author":"Choy","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.ucl.2017.07.003_bib13","first-page":"465","article-title":"The potential impact of reproducibility of Gleason grading in men with early stage prostate cancer managed by active surveillance: a multi-institutional study","volume":"186","author":"McKenney","year":"2011","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2017.07.003_bib14","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1464-410X.2012.11611.x","article-title":"Prognostic Gleason grade grouping: data based on the modified Gleason scoring system","volume":"111","author":"Pierorazio","year":"2013","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ucl.2017.07.003_bib15","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system","volume":"40","author":"Epstein","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ucl.2017.07.003_bib16","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A\u00a0contemporary prostate cancer grading system: a validated alternative to the Gleason score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2017.07.003_bib17","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.eururo.2015.11.036","article-title":"Evaluation of the 2015 Gleason grade groups in a nationwide population-based cohort","volume":"69","author":"Loeb","year":"2016","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2017.07.003_bib18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/pros.23265","article-title":"The new prostate cancer grading system does not improve prediction of clinical recurrence after radical prostatectomy: results of a large, two-center validation study","volume":"77","author":"Dell'Oglio","year":"2017","journal-title":"Prostate"},{"issue":"10","key":"10.1016\/j.ucl.2017.07.003_bib19","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/bjc.2016.86","article-title":"Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome","volume":"114","author":"Berney","year":"2016","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.ucl.2017.07.003_bib20","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.eururo.2016.11.032","article-title":"Application of a prognostic Gleason grade grouping system to assess distant prostate cancer outcomes","volume":"71","author":"Leapman","year":"2017","journal-title":"Eur Urol"},{"issue":"24","key":"10.1016\/j.ucl.2017.07.003_bib21","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1002\/cncr.27670","article-title":"The quantitative Gleason score improves prostate cancer risk assessment","volume":"118","author":"Reese","year":"2012","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ucl.2017.07.003_bib22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.eururo.2015.10.026","article-title":"Size-adjusted quantitative Gleason score as a predictor of biochemical recurrence after radical prostatectomy","volume":"70","author":"Deng","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.ucl.2017.07.003_bib23","article-title":"Integrating tertiary Gleason 5 patterns into quantitative Gleason grading in prostate biopsies and prostatectomy specimens","author":"Sauter","year":"2017","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.ucl.2017.07.003_bib24","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D'Amico","year":"1998","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ucl.2017.07.003_bib25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.5489\/cuaj.11085","article-title":"Pre-treatment risk stratification of prostate cancer patients: a critical review","volume":"6","author":"Rodrigues","year":"2012","journal-title":"Can Urol Assoc J"},{"issue":"1","key":"10.1016\/j.ucl.2017.07.003_bib26","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1200\/JCO.1999.17.1.168","article-title":"Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer","volume":"17","author":"D'Amico","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2017.07.003_bib27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/cncr.25596","article-title":"Inaccuracies in assignment of clinical stage for localized prostate cancer","volume":"117","author":"Reese","year":"2011","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2017.07.003_bib28","first-page":"114","article-title":"Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease","volume":"184","author":"Reese","year":"2010","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2017.07.003_bib29","doi-asserted-by":"crossref","first-page":"f7524","DOI":"10.1136\/bmj.f7524","article-title":"Prostate cancer: summary of updated NICE guidance","volume":"348","author":"Graham","year":"2014","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.ucl.2017.07.003_bib30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.6004\/jnccn.2010.0012","article-title":"NCCN clinical practice guidelines in oncology: prostate cancer","volume":"8","author":"Mohler","year":"2010","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.ucl.2017.07.003_bib31","first-page":"2106","article-title":"Guideline for the management of clinically localized prostate cancer: 2007 update","volume":"177","author":"Thompson","year":"2007","journal-title":"J\u00a0Urol"},{"issue":"10","key":"10.1016\/j.ucl.2017.07.003_bib32","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/jnci\/90.10.766","article-title":"A\u00a0preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer","volume":"90","author":"Kattan","year":"1998","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.ucl.2017.07.003_bib33","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.6004\/jnccn.2016.0149","article-title":"Validation of the Kattan nomogram for prostate cancer recurrence after radical prostatectomy","volume":"14","author":"Ondracek","year":"2016","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"26","key":"10.1016\/j.ucl.2017.07.003_bib34","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1200\/JCO.2008.18.2501","article-title":"Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era","volume":"27","author":"Stephenson","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2017.07.003_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/21681805.2016.1266384","article-title":"Development of a new nomogram to predict insignificant prostate cancer in patients undergoing radical prostatectomy","volume":"51","author":"Kim","year":"2017","journal-title":"Scand J Urol"},{"key":"10.1016\/j.ucl.2017.07.003_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2015.11.004","article-title":"Predicting survival of men with recurrent prostate cancer after radical prostatectomy","volume":"54","author":"Dell'Oglio","year":"2016","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ucl.2017.07.003_bib37","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/cncr.26306","article-title":"Clinically significant Gleason sum upgrade: external validation and head-to-head comparison of the existing nomograms","volume":"118","author":"Iremashvili","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ucl.2017.07.003_bib38","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/pcan.2012.21","article-title":"Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram","volume":"15","author":"Kutikov","year":"2012","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.ucl.2017.07.003_bib39","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.eururo.2009.12.003","article-title":"Head-to-head comparison of the three most commonly used preoperative models for prediction of biochemical recurrence after radical prostatectomy","volume":"57","author":"Lughezzani","year":"2010","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.ucl.2017.07.003_bib40","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1002\/cncr.23908","article-title":"An updated catalog of prostate cancer predictive tools","volume":"113","author":"Shariat","year":"2008","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.ucl.2017.07.003_bib41","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1158\/1078-0432.CCR-07-4713","article-title":"Comparison of nomograms with other methods for predicting outcomes in prostate cancer: a critical analysis of the literature","volume":"14","author":"Shariat","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.ucl.2017.07.003_bib42","first-page":"1938","article-title":"The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy","volume":"173","author":"Cooperberg","year":"2005","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2017.07.003_bib43","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2016.08.065","article-title":"The CAPRA score at 10 years: contemporary perspectives and analysis of supporting studies","volume":"71","author":"Brajtbord","year":"2017","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.ucl.2017.07.003_bib44","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1002\/cncr.22262","article-title":"Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy","volume":"107","author":"Cooperberg","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ucl.2017.07.003_bib45","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.radonc.2011.05.080","article-title":"The cancer of the prostate risk assessment (CAPRA) in patients treated with external beam radiation therapy: evaluation and optimization in patients at higher risk of relapse","volume":"101","author":"Halverson","year":"2011","journal-title":"Radiother Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2017.07.003_bib46","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.urology.2014.05.032","article-title":"Analysis of the cancer of the prostate risk assessment to predict for biochemical failure after external beam radiotherapy or prostate seed brachytherapy","volume":"84","author":"Delouya","year":"2014","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.ucl.2017.07.003_bib47","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/bju.12587","article-title":"The cancer of the prostate risk assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy","volume":"114","author":"Krishnan","year":"2014","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ucl.2017.07.003_bib48","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/COC.0000000000000037","article-title":"Limitations of the cancer of the prostate risk assessment (CAPRA) prognostic tool for prediction of metastases and prostate cancer-specific mortality in patients treated with external beam radiation therapy","volume":"39","author":"Vainshtein","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ucl.2017.07.003_bib49","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1093\/jjco\/hyr136","article-title":"External validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese patients receiving radical prostatectomy","volume":"41","author":"Ishizaki","year":"2011","journal-title":"Jpn J Clin Oncol"},{"issue":"Suppl 2","key":"10.1016\/j.ucl.2017.07.003_bib50","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1464-410X.2011.10687.x","article-title":"Comparative analysis of three risk assessment tools in Australian patients with prostate cancer","volume":"108","author":"Tamblyn","year":"2011","journal-title":"BJU Int"},{"issue":"7637","key":"10.1016\/j.ucl.2017.07.003_bib51","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nature20788","article-title":"Genomic hallmarks of localized, non-indolent prostate cancer","volume":"541","author":"Fraser","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.ucl.2017.07.003_bib52","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1470-2045(10)70295-3","article-title":"Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2017.07.003_bib53","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/bjc.2015.223","article-title":"Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort","volume":"113","author":"Cuzick","year":"2015","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.ucl.2017.07.003_bib54","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11934-015-0545-3","article-title":"What is the need for prostatic biomarkers in prostate cancer management?","volume":"16","author":"Spahn","year":"2015","journal-title":"Curr Urol Rep"},{"issue":"6","key":"10.1016\/j.ucl.2017.07.003_bib55","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/bjc.2012.39","article-title":"Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort","volume":"106","author":"Cuzick","year":"2012","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ucl.2017.07.003_bib56","first-page":"409","article-title":"Prognostic utility of the cell cycle progression score generated from biopsy in men treated with prostatectomy","volume":"192","author":"Bishoff","year":"2014","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2017.07.003_bib57","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.urology.2016.11.038","article-title":"Cell-cycle progression-score might improve the current risk assessment in newly diagnosed prostate cancer patients","volume":"102","author":"Oderda","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2017.07.003_bib58","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1186\/1471-2164-14-690","article-title":"Analytical validation of the oncotype DX prostate cancer assay: a clinical RT-PCR assay optimized for prostate needle biopsies","volume":"14","author":"Knezevic","year":"2013","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ucl.2017.07.003_bib59","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12916-016-0613-7","article-title":"Incorporation of tissue-based genomic biomarkers into localized prostate cancer clinics","volume":"14","author":"Moschini","year":"2016","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.ucl.2017.07.003_bib60","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.eururo.2014.05.004","article-title":"A\u00a017-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling","volume":"66","author":"Klein","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ucl.2017.07.003_bib61","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2014.11.030","article-title":"A\u00a0biopsy-based 17-gene genomic prostate score predicts recurrence after radical prostatectomy and adverse surgical pathology in a racially diverse population of men with clinically low- and intermediate-risk prostate cancer","volume":"68","author":"Cullen","year":"2015","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ucl.2017.07.003_bib62","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jmoldx.2015.12.006","article-title":"Application of a clinical whole-transcriptome assay for staging and prognosis of prostate cancer diagnosed in needle core biopsy specimens","volume":"18","author":"Knudsen","year":"2016","journal-title":"J\u00a0Mol Diagn"},{"issue":"1","key":"10.1016\/j.ucl.2017.07.003_bib63","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/pcan.2013.49","article-title":"A\u00a0genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy","volume":"17","author":"Ross","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.ucl.2017.07.003_bib64","doi-asserted-by":"crossref","first-page":"e66855","DOI":"10.1371\/journal.pone.0066855","article-title":"Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy","volume":"8","author":"Erho","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.ucl.2017.07.003_bib65","first-page":"2047","article-title":"Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population","volume":"190","author":"Karnes","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.ucl.2017.07.003_bib66","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.urology.2016.01.012","article-title":"Decipher genomic classifier measured on prostate biopsy predicts metastasis risk","volume":"90","author":"Klein","year":"2016","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.ucl.2017.07.003_bib67","doi-asserted-by":"crossref","first-page":"19","DOI":"10.6004\/jnccn.2016.0004","article-title":"Prostate cancer, version 1.2016","volume":"14","author":"Mohler","year":"2016","journal-title":"J\u00a0Natl Compr Canc Netw"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014317300745?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014317300745?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:34:58Z","timestamp":1758807298000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014317300745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0094014317300745"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2017.07.003","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Whom to Treat","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2017.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}